Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.

BMC Cancer · 2018 · PMC6027771 · PMID 29954358

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendP = 0.09so close (0.05 < p ≤ 0.1)

Compared with the FLO group, the FLOT group showed a trend towards an improved median PFS (21.1 vs 12.0 months; P = 0.09).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.